Castle Biosciences (NASDAQ:CSTL – Get Rating) had its price target dropped by research analysts at Robert W. Baird from $35.00 to $25.00 in a report issued on Monday, The Fly reports. Robert W. Baird’s target price points to a potential upside of 69.84% from the stock’s previous close. Other equities research analysts also recently issued […]
Castle Biosciences (NASDAQ:CSTL – Get Rating) had its price objective decreased by equities research analysts at Scotiabank from $54.00 to $33.00 in a research note issued on Wednesday, The Fly reports. Scotiabank’s price target suggests a potential upside of 124.34% from the company’s current price. A number of other equities analysts also recently weighed in […]
Castle Biosciences, Inc. (NASDAQ:CSTL – Get Rating) Director Ellen Goldberg acquired 4,800 shares of the stock in a transaction dated Monday, June 5th. The stock was acquired at an average cost of $14.38 per share, with a total value of $69,024.00. Following the completion of the transaction, the director now owns 9,065 shares in the […]
Castle Biosciences, Inc. (NASDAQ:CSTL – Get Rating) Director Daniel Bradbury sold 17,643 shares of the firm’s stock in a transaction on Thursday, May 4th. The stock was sold at an average price of $21.69, for a total transaction of $382,676.67. Following the completion of the sale, the director now owns 79,251 shares of the company’s […]
Castle Biosciences (NASDAQ:CSTL – Get Rating) had its price objective lowered by Robert W. Baird from $38.00 to $35.00 in a research report released on Thursday, The Fly reports. A number of other analysts also recently issued reports on CSTL. Lake Street Capital cut their price objective on shares of Castle Biosciences from $63.00 to […]